🇺🇸 MK-0518 in United States

65 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 9 reports (13.85%)
  2. Pyrexia — 8 reports (12.31%)
  3. Renal Failure Acute — 8 reports (12.31%)
  4. Blood Alkaline Phosphatase Increased — 7 reports (10.77%)
  5. Anaemia — 6 reports (9.23%)
  6. Nausea — 6 reports (9.23%)
  7. Vomiting — 6 reports (9.23%)
  8. Adrenal Insufficiency — 5 reports (7.69%)
  9. Dehydration — 5 reports (7.69%)
  10. Drug Hypersensitivity — 5 reports (7.69%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is MK-0518 approved in United States?

MK-0518 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for MK-0518 in United States?

Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.